|
|
Article: Agendia Publishes Direct Evidence That MammaPrint Predicts Benefit of Chemotherapy in Breast Cancer.
- Article from:
- PR Newswire
- Article date:
- February 18, 2009
CopyrightCOPYRIGHT 2009 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Findings Published in Peer-Reviewed Journal, Breast Cancer Research and Treatment
HUNTINGTON BEACH, California, and AMSTERDAM, February 18 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced that a study demonstrating the direct predictive ability of its breast cancer recurrence test, MammaPrint(R), has been published in Breast Cancer Research and Treatment. Additionally, the study authors have been invited to present the data at the American Association for Cancer Research's 2009 Annual Meeting in Denver, Colorado.
"Our multi-study pool of patient data is maturing quickly and this is the first of a number of ...